Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

詳細情報 詳細情報について

• CRID

  1360002216450157952

• DOI

  10.1016/s1470-2045(14)70381-x

• ISSN

  14702045

• Web Site

  https://api.elsevier.com/content/article/PII:S147020451470381X?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S147020451470381X?httpAccept=text/plain

• データソース種別

  • Crossref
  • KAKEN